Portolan Capital Management’s Castle Biosciences CSTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$48.8M Buy
1,372,870
+1,044,052
+318% +$31.5M 1.99% 8
2026
Q2
$7.84M Sell
328,818
-1,021,465
-76% -$22.8M 0.29% 95
2026
Q1
$33.1M Sell
1,350,283
-379,180
-22% -$12.4M 1.76% 15
2025
Q4
$67.3M Buy
1,729,463
+214,352
+14% +$6.91M 3.6% 3
2025
Q3
$34.5M Buy
1,515,111
+25,539
+2% +$519K 1.87% 15
2025
Q2
$30.4M Buy
1,489,572
+224,349
+18% +$4.15M 1.91% 12
2025
Q1
$25.3M Buy
1,265,223
+488,644
+63% +$12.1M 1.93% 11
2024
Q4
$20.7M Sell
776,579
-479,049
-38% -$14.6M 1.39% 20
2024
Q3
$35.8M Buy
1,255,628
+44,676
+4% +$1.14M 2.6% 6
2024
Q2
$26.4M Buy
1,210,952
+167,542
+16% +$3.73M 2.17% 10
2024
Q1
$23.1M Buy
1,043,410
+314,757
+43% +$6.85M 1.76% 14
2023
Q4
$15.7M Buy
728,653
+475,625
+188% +$8.37M 1.37% 17
2023
Q3
$4.27M Sell
253,028
-178,446
-41% -$3.12M 0.4% 77
2023
Q2
$5.92M Buy
431,474
+174,825
+68% +$3.54M 0.52% 58
2023
Q1
$5.83M Sell
256,649
-327,067
-56% -$7.99M 0.56% 63
2022
Q4
$13.7M Buy
583,716
+283,126
+94% +$6.56M 1.36% 24
2022
Q3
$7.84M Buy
300,590
+145,622
+94% +$4.08M 0.83% 41
2022
Q2
$3.4M Buy
+154,968
New +$3.6M 0.34% 93
2021
Q3
– Sell
-9,127
Closed -$669K – 136
2021
Q2
$669K Buy
+9,127
New +$603K 0.05% 125
2021
Q1
– Sell
-16,573
Closed -$1.11M – 162
2020
Q4
$1.11M Sell
16,573
-11,059
-40% -$599K 0.1% 133
2020
Q3
$1.42M Sell
27,632
-44,202
-62% -$1.97M 0.16% 125
2020
Q2
$2.71M Sell
71,834
-63,820
-47% -$2.18M 0.31% 101
2020
Q1
$4.04M Sell
135,654
-169,924
-56% -$5.13M 0.61% 53
2019
Q4
$10.5M Buy
305,578
+180,647
+145% +$4.42M 1.06% 37
2019
Q3
$2.26M Buy
+124,931
New +$2.77M 0.25% 77

Other funds holding CSTL

Portolan Capital Management's CSTL Position: Q3 2026 in Review

Portolan Capital Management increased its Castle Biosciences (CSTL) stake by 318% in Q3 2026, buying an estimated $31.5M and bringing the position to 1,372,870 shares worth $48.8M. The position accounts for 1.99% of the portfolio, ranked #8.

Portolan Capital Management first reported a position in CSTL in Q3 2019 and has held it in 25 quarters since. The position peaked at $67.3M in Q4 2025. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Portolan Capital Management held 1,372,870 shares of Castle Biosciences worth $48.8M as of Q3 2026.
  • Portolan Capital Management bought 1,044,052 Castle Biosciences shares in Q3 2026, an estimated $31.5M.
  • Castle Biosciences made up 1.99% of Portolan Capital Management's portfolio in Q3 2026, its #8 holding.
  • Portolan Capital Management first reported a position in Castle Biosciences in Q3 2019 and has held it in 25 quarters since.
  • Portolan Capital Management's Castle Biosciences position peaked at $67.3M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Portolan Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.